Back to Blog
Diabetes Basics October 14, 2026 SweetLife Team

Type 1 Diabetes Life Expectancy: What the Numbers Say, and What They Leave Out

It is one of the first things people search after a diagnosis, often late at night, and the answers range from falsely reassuring to frightening. The honest version: large studies do find a gap in life expectancy. They also show where that gap comes from — and much of it comes from things modern care is built to prevent or treat.

This article summarizes published research. It is not a prediction for any one person. Population averages describe large groups and say very little about a single person's future.

What the Biggest Studies Found

The most quoted figure comes from Scotland. Researchers followed every adult with type 1 diabetes in the national register — more than 24,000 people — using data from 2008 to 2010. At age 20, men with type 1 could expect about 46 more years of life, against 57 for men without it. Women could expect about 48 more years, against 61. That is a gap of roughly 11 years for men and 13 for women.

A Swedish study published in The Lancet in 2018 compared more than 27,000 people with type 1 against 135,000 matched people without it, and found that age at diagnosis mattered a great deal: the excess risk of dying differed by up to five times across diagnosis ages. People diagnosed before age 10 lost an estimated 17.7 years of life for women and 14.2 for men. The excess risk was lower for people diagnosed in their late twenties, though still well above that of people without diabetes.

Why Those Numbers Are Already Old

Life expectancy studies have to look backward. To measure how long people live with a condition, you need people who have already lived with it for decades — so these figures describe people diagnosed years or decades earlier and treated with the tools of their time.

The Scottish authors made the point themselves: major advances in type 1 treatment had happened over the previous three decades, which is why they set out to produce contemporary estimates. But continuous glucose monitors and automated insulin delivery systems have not been in wide use long enough for any study to measure their effect over a lifetime. Today's numbers are not in these studies yet.

Where the Gap Comes From

The Scottish study broke the loss down by cause, and the answer is not mysterious:

The Swedish study points the same way. The excess risk of heart attack, heart failure and other cardiovascular disease was highest in people diagnosed young, and women carried the highest excess risk. Its authors concluded that people with early-onset type 1 may need a greater focus on protecting their hearts.

The Part That Is Within Reach

Look at that list again: heart disease, DKA, kidney disease. These are among the most studied and most treatable parts of diabetes care.

Glucose management pays off over decades. The DCCT, the trial that established modern intensive insulin therapy, has followed its participants for an average of 27 years. People who spent about six and a half years in the intensive-treatment group had lower all-cause mortality decades later than those in the conventional group, and higher A1C over time was associated with higher mortality. The difference was modest, but it was measurable from a few years of better control, decades earlier.

The heart needs as much attention as glucose. The ADA recommends checking blood pressure at every routine visit, with a target under 130/80 mmHg when it can be safely reached, and managing cholesterol. Given where the lost years come from, this is not a side issue.

DKA has known triggers. The most common are missed or interrupted insulin and illness or infection. Knowing the warning signs, checking ketones when you are sick, and never stopping basal insulin address those directly. Our guide to sick day rules covers the details.

Screening finds problems while they are treatable. Yearly kidney tests, regular dilated eye exams and an annual foot exam catch complications early, often before any symptoms.

What the Numbers Cannot Tell You

An average across tens of thousands of people folds together every kind of life: people diagnosed in different decades, with different access to care, different kidney health and different circumstances. It cannot tell any one person how long they will live. What it can do is show which risks deserve the most attention — and those turn out to be the ones good diabetes care already focuses on.

Where SweetLife Fits

SweetLife tracks the numbers that sit underneath long-term risk: time in range, estimated A1C and GMI, and how variable your glucose is. Over months, those trends are what you and your care team actually act on. The doctor report, part of Plus, puts your recent data in front of your endocrinologist at each appointment.

The Short Version

Large studies from Scotland and Sweden found that type 1 diabetes shortened life expectancy by about 11 to 13 years on average, and more for people diagnosed in early childhood. Those figures describe people treated with older tools, and most of the gap comes from heart disease, DKA and kidney disease — all things modern care targets directly. A few years of better glucose control was linked to lower mortality decades later, and blood pressure and cholesterol matter as much as glucose does.

Sources

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or changes to your diabetes management plan, including medication, insulin dosing, and pre-bolusing timing. SweetLife is a tracking and logging tool, not a medical device, and does not provide medical advice.

Back to Blog